| Literature DB >> 30005854 |
Augusto Vaglio1, Peter C Grayson2, Paride Fenaroli3, Davide Gianfreda3, Valeria Boccaletti4, Gian Marco Ghiggeri5, Gabriella Moroni6.
Abstract
Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong associations with newer agents, such as TNF α (TNFα) inhibitors, are increasingly recognised. The pathogenic mechanisms explaining how drugs that have heterogeneous chemical structure and function lead to autoimmunity are only partially understood. However, it is likely that traditional DIL-associated agents can boost innate immune responses, particularly neutrophil responses, with neutrophil extracellular trap (NET) formation and exposure of autoantigens. Research in the field of DIL is evolving and may provide interesting models for the study of autoimmunity.Entities:
Keywords: Anti-nuclear antibodies; Autoimmunity; Lupus; NETosis; TNF inhibitors
Mesh:
Year: 2018 PMID: 30005854 DOI: 10.1016/j.autrev.2018.03.016
Source DB: PubMed Journal: Autoimmun Rev ISSN: 1568-9972 Impact factor: 9.754